Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses

Journal of Virology

Volumn 79, Issue 9, 2005, Pages 5455-5465

  Zhu, Mingzhu ^a   Bristol, J Andrew ^a   Xie, Yuefeng ^a   Mina, Mervat ^a   Ji, Hong ^a   Forry Schaudies, Suzanne ^a   Ennist, David L ^a,b   Bryan, Susan ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Cell Genesys Inc ^*  (United States)

^c CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN; GLYCOPROTEIN GP 19; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA PACKAGING; DNA SEQUENCE; FEMALE; GENE INSERTION; HUMAN; HUMAN CELL; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E2 PROTEINS; ADENOVIRUS E3 PROTEINS; ANIMALS; CAPSID PROTEINS; FEMALE; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS (GENETICS); TRANSGENES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 17444377930     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.9.5455-5465.2005     Document Type: Article

References (37)

1. Andersson, M., S. Paabo, T. Nilsson, and P. A. Peterson. 1985. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 43:215-222.
2. Bauzon, M., D. Castro, M. Karr, L. K. Hawkins, and T.W. Hermiston. 2003. Multigene expression from a replicating adenovirus using native viral promoters. Mol. Ther. 7:526-534.
3. Bristol, J. A., M. Zhu, J. H., M. Mina, Y. Xie, L. Clarke, S. Forry-schaudies, and D. L. Ennist. 2003. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol. Ther. 7:755-764.
4. Burgert, H. G., and S. Kvist. 1985. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 41:987-997.
5. Chartier, C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70:4805-4810.
6. Doronin, K., M. Kuppuswamy, K. Toth, A. E. Tollefson, P. Krajcsi, V. Krougliak, and W. S. Wold. 2001. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75:3314-3324.
7. Doronin, K., K. Toth, M. Kuppuswamy, P. Ward, A. E. Tollefson, and W. S. Wold. 2000. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74:6147-6155.
8. Frauwirth, K. A., and C. B. Thompson. 2002. Activation and inhibition of lymphocytes by costimulation. J. Clin. Investig. 109:295-299.
9. Ghattas, I. R., J. R. Sanes, and J. E. Majors. 1991. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol. Cell. Biol. 11:5848-5859.
10. Gorziglia, M. I., M. J. Kadan, S. Yei, J. Lim, G. M. Lee, R. Luthra, and B. C. Trapnell. 1996. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70: 4173-4178.
11. Harrison, D., H. Sauthoff, S. Heitner, J. Jagirdar, W. N. Rom, and Hay, J. G. 2001. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum. Gene Ther. 12:1323-1332.
12. Hawkins, L. K., and T. W. Hermiston. 2001. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region. Gene Ther. 8:1132-1141.
13. Hawkins, L. K., and T. W. Hermiston. 2001. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region. Gene Ther. 8:1142-1148.
14. Hawkins, L. K., L. Johnson, M. Bauzon, J. A. Nye, D. Castro, G. A. Kitzes, M. D. Young, J. K. Holt, P. Trawn, and T. W. Hermiston. 2001. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7K/gp19K region. Gene Ther. 8:1123-1131.
15. He, T. C., Z;, S., D. A. L. T. Costa, Yu, J., K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95:2509-2514.
16. Horton, R. M., Z. L. Cai, Ho, S. N., and L.R. Pease. 1990. Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction. BioTechniques 8:528-535.
17. Horwitz, M. S. 2001. Adenovirus immunoregulatory genes and their cellular targets. Virology 279:1-8.
18. Jakubczak, J. L., M. L. Rollence, D. A. Stewart, et al. 2001. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J. Virol. 75:2972-2981.
19. Jakubczak, J. L., P. Ryan, M. Gorziglia, et al. 2003. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. 63:1490-1499.
20. Jones, N., and T. Shenk. 1979. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 17: 683-689.
21. Kozak, M. 1991. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J. Biol. Chem. 266:19867-19870.
22. Mittereder, N., K. L. March, and B. C. Trapnell. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:7498-7509.
23. Mwangi, W., W. C. Brown, H. A. Lewin, C. J. Howard, J. C. Hope, T. V. Baszler, P. Caplazi, J. Abbott, and G. H. Palmer. 2002. DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNA vaccination of outbred animals. J. Immunol. 169:3837-3846.
24. Parr, M. J., Y. Manome, T. Tanaka, P. Wen, D. W. Kufe, W. G. Kaelin, Jr., and H. A. Fine. 1997. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 3:1145-1149.
25. Rodriguez, R., E. R. Schuur, H. Y. Lim, G. A. Henderson, J. W. Simons, and D. R. Henderson. 1997. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:2559-2563.
26. Russell, W.C. 2000. Update on adenovirus and its vectors. J. Gen. Virol. 81:2573-2604.
27. Sauthoff, H., Hu, J., C. Maca, M. Goldman, S. Heitner, H. Yee, T. Pipiya, W. N. Rom, and J. G. Hay. 2003. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum. Gene Ther. 14:425-433.
28. Sparer, T. E., R. A. Tripp, D. L. Dillehay, T. W. Hermiston, W. S. Wold, and L. R. Gooding. 1996. The role of human adenovirus early region 3 proteins (gp19K, 14.5K, and 14.7K) in a murine pneumonia model. J. Virol. 70:2431-2439.
29. Tollefson, A. E., A. Scaria, T. W. Hermiston, J. S. Ryerse, L. J. Wold, and W. S. Wold. 1996. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70:2296-2306.
30. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146.
31. Tsukuda, K., Wlewrodt, R., K. Molnar-kimber, V. P. Jovanovic, and K. M. Amin. 2002. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res. 62:3438-3447.
32. Wirth, T., L. Zender, B. Schulte, B. Mundt, R. Plentz, K. L. Rudolph, M. Manns, S. Kubicka, and F. Kuhnel. 2003. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 63:3181-3188.
33. Wold, W. S., K. Doronin, K. Toth, M. Kuppuswamy, D. L. Lichtenstein, and A. E. Tollefson. 1999. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr. Opin. Immunol. 11: 380-386.
34. Wold, W. S., and L. R. Gooding. 1991. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 184:1-8.
35. Wold, W. S., A. E. Tollefson, and T. W. Hermiston. 1995. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol. 199:237-274.
36. Yu, D. C., Y. Chen, M. Seng, J. Dilley, and D. R. Henderson. 1999. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59:4200-4203.
37. Yu, D. C., G. T. Sakamoto, and D. R. Henderson. 1999. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of Calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59:1498-1504.